Brez internetne povezave — prikazana je shranjena različica strani.

TELIX Pharmaceuti…

AUAUD
← Na filter delnic

TELIX Pharmaceuticals Ltd (AU:TLX) — Biotechnology: Pharmaceutical Preparations. Število borz, na katerih se trgujejo delnice družbe: 2. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.

O podjetju

Spletna stran
telixpharma.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Sedež
NORTH MELBOURNE, Australia
Izvršni direktor
Christian P. Behrenbruch BEng(Hons)
Zaposleni
1 120
Delnice v obtoku
338.78 mio.
Prosto prenosljive delnice
273.61 mio.
Tržna kapitalizacija
5.37 mrd. AUD
Notranje osebe
15.81%
Institucionalni vlagatelji
34.17%
Panoga (SIC)
Pharmaceutical Preparations
Delež izplačila
0%
FCF
−43.0 mio. USD
Dolg
418 mio. USD
Dividendni staž
—
Dobički, FCF in izplačane dividende — za 12 mesecev do 31.12.2025 (najnovejše poročilo podjetja).
Opis

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Borze in oznake

BorzaOznakaValutaCenaVrsta
AU Australian Securities ExchangeTLX glavnaAUD15.85 +0.00%navadne delnice
US USA StocksTLPPF OTCUSD10.95 +0.00%navadne delnice

Cena v 3 mesecih

dan rasti dan padca ex-dividendni datum datum izplačilaPremaknite miško / tapnite dan — otvoritvena, zaključna, najvišja in najnižja cena

Dividende

Ni bilo najdenih izplačil dividend (preverjeno 10.10.2026). Podjetje verjetno ne izplačuje dividend.

Novice ta teden

Novic s spletnega mesta podjetja še ni.

oglas

Največji imetniki

ImetnikDeležDelniceDatum poročila
Behrenbruch (Christian P…≈6.31%21.4 mio.2026-04-29
VANGUARD STAR FUNDS-Vang…1.21%4.1 mio.2026-07-31
VANGUARD TAX-MANAGED FUN…0.81%2.74 mio.2026-06-30
DFA INVESTMENT TRUST CO-…0.33%1.13 mio.2026-07-31
VANGUARD Intl Eqy. INDEX…0.19%652 3312026-07-31
SCHWAB STRATEGIC TRUST-S…0.18%613 5272026-05-31
Fidelity Rutland Square…0.1%339 9652026-07-31
VANGUARD Intl Eqy. INDEX…0.09%298 3222026-07-31
VANGUARD Intl Eqy. INDEX…0.07%233 3212026-07-31
College Retirement Equit…0.06%202 5482026-06-30
Fidelity Salem Street Tr…0.05%156 8512026-07-31
Olson (Tiffany) (Indepen…≈0.03%106 5502025-03-05
McDonald (Marie Elizabet…≈0%3 7192025-03-05
Kluge (Andreas) (Former)—02024-10-17
McCann (Harry Kevin) (Fo…—02025-05-21